Physician profile
Clayton G Van Balen
NPI 1316943251
$1,092.16
in general payments reported to CMS, 2019-2025
12 companies · $366 in 2025
The $366 reported for 2025 was more than what 85% of Occupational Medicine providers received nationally (typical 2025 total: $53.66).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $216 · 2024: $510 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $341.72 | 2023-2025 | Mounjaro, Zepbound, Basaglar |
| E.R. Squibb & Sons, L.L.C. | $220.67 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $124.63 | 2023-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $96.62 | 2023-2025 | |
| Daiichi Sankyo INC. | $64.81 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $52.97 | 2023-2025 | Ozempic, Rybelsus |
| Vertex Pharmaceuticals Incorporated | $47.41 | 2025 | |
| Exact Sciences Corporation | $43.82 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $36.23 | 2025 | |
| Boston Scientific Corporation | $30.86 | 2024 | Watchman Flx |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $14.11 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Van Balen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.